The transition to a quality management system (QMS) in accordance with ISO 9001:2000 has been made in November 2000.

Based on our experience with the production of high quality and reliable diagnostics for biopharmaceutical quality control, Minerva Biolabs transferred this know-how to the development of clinical diagnostics for respiratory infections in 2001.

The consequential expansion of our product range led in the beginning of 2004 to the introduction of the worldwide first bacterial diagnostic assay. Another innovative improvement followed the same year by the integration of the Aqua Screen® System into the portfolio of contamination control solutions. The Aqua Screen® System provides a highly efficient method for the filtration and detection of legionella in water. The transition to a quality management system in accordance with ISO 13485:2003 has been made in July 2004.

As a direct result of our steadily expanding product portfolio, we are pleased to present our first product catalogue at the beginning of 2005.

Minerva Biolabs develops two new products for the PCR Detection and the control of microbial contaminants. The PCR-Assays Venor^®GeM-qEP and Venor^®GeM-qDual can be used for the detection of mycoplasma DNA. Both products were launched in the beginning of 2007.

In June, Minerva opens its new company building with state of the art laboratories, production facilities and offices on the site of the Vivantes-Wilhelm-Griesinger hospital in Berlin-Marzahn.

In the beginning of the year, Minerva Biolabs expands his product range with two new clinical test kits Onar^®MRSA and Onar^®Tp. Onar^®MRSA in vitro test system for quantitative and rapid PCR-based detection of Methicillin-resistant Staphylococcus aureus in clinical samples. Another innovative improvement followed with Mynox^®Gold, a further development of the classical Mynox®, which was known for a very high elimination efficiency and low cytotoxicity. Mynox^®Gold is a combination of a standard antibiotic and a biological reagent.

Minerva Biolabs developed the PCR Assay Venor^®GeM Advance, a further development of the classical Venor^®GeM PCR Detection Kit. Another innovative development followed the same year with ZellShield^® – The Cell Culture Contamination Preventive, which protects cell cultures from most intracellular and extracellular growing gram negative and gram positive bacteria, mycoplasma, protozoon, fungi and yeast.

Minerva accuses back into the Innovationspark Wuhlheide in Berlin Koepenick for a 890 square meter laboratory and office space. The production facility in Marzahn is reduced and is only used for the production of our positive controls.

New orders: Minerva rises in the classic culture method for diagnosis of Legionella. Together with the entire diagnostic service, it has been accredited in accordance with DIN EN ISO 17025. The mycoplasma diagnostic service also receives the GMP status.

The production of clinical diagnostics products is discontinued due to the competitive pressure of leading market players. The capabilities and capacities for the design and manufacture of IVDs are now offered as contract manufacturing services.

The service division spins off. From now on, Minerva Analytix GmbH offers a specific portfolio of testing services.
The companies Minerva Biolabs and Minerva Analytix are transferred to the holding company Dilarus.

The contract manufacturing division keeps growing. We need more space soon. The development of a new product line begins: products for sensitive bacteria detection based on qPCR to replace culture-based sterility testing.

We start planning a new company location and a new building in order to expand our capacities.

We are back in Berlin-Marzahn. We triple our capacities and move into a building tailored to our needs. Highly technical. Energy-efficient. With a cool design.